GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology’s Unique Performance in Identifying Patients with “at-risk” NASH

NEXT STORY
Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China
PREV STORY
Sight Sciences to Participate in the Upcoming Piper Sandler Annual Healthcare Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

NewLink Genetics Announces Initial Phase 1 Data with Indoximod Plus Radiation and Chemotherapy for Pediatric Patients with Diffuse Intrinsic Pontine Glioma (DIPG) Presented During AACR Plenary

author_avatar
NASDAQ Market News

Clearside Biomedical, Inc. Announces Third Quarter 2017 Financial Results and Provides Corporate Update

ALPHARETTA, Ga., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage ...

author_avatar
NASDAQ Market News

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

author_avatar
NASDAQ Market News